MEK inhibitors | GenomeWeb

MEK inhibitors

One of the first projects between the firms will be to develop and commercialize a companion diagnostic for the MEK inhibitor binimetinib in NRAS-mutant melanoma.

Before patients receive the Cotellic/Zelboraf combination, patients should be tested with an FDA-approved BRAF mutation companion test, the agency said.

"Seeing that we have had other agents in this class, there should be some sort of selection of tumor types, or some type of genomic profiling, or at least retainment of archival tissue, so that we can go on to profile these patients at a later date," said Patricia LoRusso of Karmanos Cancer Institute at Wayne State University, who reviewed early dosing trials of three MEK inhibitors being developed by GlaxoSmithKline, Merck Serono, and Eisai.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.